Burning Rock Biotech is a China biotech company that primarily develops and provides cancer therapy selection tests. The company was founded in 2014 and is headquartered in Guangzhou, China.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Burning Rock Biotech news
31.05.2022
Burning Rock Biotech's IFRS loss for 3 months of 2022 was CN¥261.388 million, up 52.5% from CN¥171.411 million in the previous year. Revenue increased 27.1% to CN¥135,524 million versus CN¥106,623 million a year earlier.
Source: 
ir.brbiotech.com
ir.brbiotech.com
22.03.2022
Burning Rock Biotech's IFRS loss for 2021 was CN¥796.697 million, up 95.6% from CN¥407.235 million in the previous year. Revenue increased 18.1% to CN¥507.862 million versus CN¥429.903 million a year earlier.
Source: ir.brbiotech.com
ir.brbiotech.com
16.11.2021
Burning Rock Biotech's IFRS loss for 9M 2021 was CN¥545.553 million, up 2.2 times from CN¥250.757 million in the previous year. Revenue increased 20.9% to CN¥360.517 million from CN¥298.181 million a year earlier.
Source: ir.brbiotech.com
ir.brbiotech.com
31.08.2021
Burning Rock Biotech's loss under IFRS for 6M 2021 was CN¥375.076 million, up three times from CN¥123.627 million in the previous year. Revenue increased 34.2% to CN¥233.902 million from CN¥174.3 million a year earlier.
Source: ir.brbiotech.com
ir.brbiotech.com
General information
| Company name | Burning Rock Biotech |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 5th Floor Building 1 No138 Xinjun Ring Road Shanghai China |
| Mailing address | 5th Floor Building 1 No138 Xinjun Ring Road Shanghai China |
| Website | brbiotech.gcs-web.com |
| Information disclosure | www.sec.gov |
English (US) 